Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Apathy, white-matter microstructure, and effort-based decision making in Parkinson’s Disease
Objective: To investigate the influence of reward and effort on behavior in PD patients with and without apathy, using a drift-diffusion model to analyze neuroimage…Modulation of autophagy and neuroinflammation by Niclosamide in MPTP Induced- Parkinson’s disease model
Objective: The current investigation aimed to investigate the neuroprotective effect of niclosamide (NI) on autophagy and neuroinflammatory pathways in Parkinson’s disease (PD). Background: Autophagy dysregulation…Alopecia in females with young onset Parkinson’s Disease: an exploratory survey
Objective: To explore the symptoms of females with young onset Parkinson's Disease (YOPD), specifically alopecia, in comparison to females with traditional onset Parkinson’s Disease (TOPD).…Oculomotor changes in the premotor stage of LRRK2- G2019S associated Parkinson’s disease.
Objective: To analyse oculomotor differences among idiopathic PD patients (iPD), LRRK2-G2019S PD patients (LRRK2-G2019S PD), asymptomatic carriers of LRRK2-G2019S mutation (AsG2019S), and controls, evaluated by…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Dystonia as presenting feature of Witteveen-kolk Syndrome
Objective: To describe the clinical heterogeneity and expand the phenotypic spectrum of Witteveen- Kolk syndrome Background: Witteveen-Kolk syndrome (WITKOS) is a neurodevelopmental condition, first described…Cortical gamma oscillations in Parkinson’s disease: ipsi- and contralateral deep brain stimulation-induced entrainment
Objective: To characterize deep brain stimulation (DBS) parameters for bilateral induction of cortical finely tuned gamma (FTG) via unilateral stimulation. Background: FTG oscillations are reported…Development of a patient journey map for people living with Parkinson’s disease
Objective: Develop a Motor Fluctuations Patient Journey Map (MFPJM) for people with Parkinson’s disease (PwP) to describe the holistic experience from pre-diagnosis through long-term treatment,…Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease
Objective: To prove the efficacy and safety of dextromethorphan/quinidine 20mg/10mg (Nuedexta®) in patients with irritability due to HD. Background: Irritability is one of HD's most…
- « Previous Page
- 1
- …
- 590
- 591
- 592
- 593
- 594
- …
- 1942
- Next Page »